A new angiogenesis prognostic index with VEGFA, PLGF, and angiopoietin 1 predicts survival in patients with advanced gastric cancer

Creative Commons License

Aktaş S. H., AKBULUT H., Yazici O., ZENGİN N., Akgün H. N., Üstüner Z., ...Daha Fazla

Turkish Journal of Medical Sciences, cilt.47, sa.2, ss.399-406, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 47 Sayı: 2
  • Basım Tarihi: 2017
  • Doi Numarası: 10.3906/sag-1509-80
  • Dergi Adı: Turkish Journal of Medical Sciences
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.399-406
  • Anahtar Kelimeler: Docetaxel, cisplatin, 5-fluorouracil, VEGFA, angiopoietin 1, placental growth factor, angiogenesis prognostic index, gastric cancer, ENDOTHELIAL-GROWTH-FACTOR, GASTROESOPHAGEAL JUNCTION, HEPATOCELLULAR-CARCINOMA, VASCULAR MORPHOGENESIS, COLORECTAL-CANCER, CHEMOTHERAPY, EXPRESSION, CISPLATIN, THERAPY, METAANALYSIS
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

© TÜBİTAK.Background/aim: The role of angiogenic factors in gastric cancer is not clear. We aimed to assess the role of vascular endothelial growth factor A (VEGFA), angiopoietin 1 (Ang-1), and placental growth factor (PlGF) in the prognosis of patients with advanced gastric cancer. Materials and methods: Thirty consecutive patients treated with a modified DCF (docetaxel, cisplatin, and fluorouracil) regimen were included in the study. The plasma VEGFA, Ang-1, and PlGF levels of the patients before treatment and following two cycles of chemotherapy were measured and evaluated as prognostic factors. Results: Poor performance status and lower Ang-1 levels were correlated with poor overall survival (OS). No significant correlation between VEGFA or PlGF and OS was found. An angiogenesis prognostic index (API) based on the levels of VEGFA, Ang-1, and PlGF was found to be highly correlated with OS. Performance status and API were found as independent prognostic factors for OS. Furthermore, a decrease in VEGFA by 25% from the pretreatment level was also found as a prognostic factor for OS independent of response to DCF regimen. Conclusion: Our results support the use of the new API including VEGFA, Ang-1, and PlGF levels in patients with advanced gastric cancer as a predictor of survival.